Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Trump administration urged to take on China's 'Pharma Death Grip
The push comes as policymakers recognize the United States relies heavily on China for key pharmaceutical materials, particularly the raw components of many antibiotics, while producing a small share domestically, China specialist Gordon Chang…
Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report
Drug resistance is outpacing industry-wide efforts, says Netherlands-based Access to Medicine Foundation in its latest Antimicrobial Resistance (AMR) Benchmark report, even as it identified seven innovative late-stage projects that targetted…
Here is Why JPMorgan is Overweight on Apellis Pharma (APLS)
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 5, Anupam Rama from JPMorgan increased the price target on Apellis Pharmaceuticals Inc. (NASDAQ:APLS) from $36 to…
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 2, Wedbush analyst Laura Chico increased the firm's price target on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to…
AP Shills For Big Pharma Antidepressants With 'Bewildering' Hit Piece
Check this out... The Trump FDA's top drug regulator, Dr. Tracy Beth Hoeg, is working to hire a researcher and friend who strongly believes the agency should add new warnings about antidepressants and pregnancy risks. So what does the Associated…
What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 20, Bank of America Securities lowered the price target on Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) from $570…
China focus: a2 Milk Company, Otsuka Pharma, HMO approval and more
This round-up looks at news from a2 Milk Company and Otsuka Pharma, the third HMO approval in China, latest scientific findings and more.
Mayne Pharma Group Limited (MAYNF) Discusses U.S. Launch and Business Model of DistributeRx Transcript
Mayne Pharma Group Limited (MAYNF) Discusses U.S. Launch and Business Model of DistributeRx March 10, 2026 8:01 PM EDT Thomas Duthy - Manager of Investor Relations Aaron Gray - Chief Executive Officer Andrew Goodsall - MST Financial Services Pty…
Louis Lange Sells 28,186 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director Louis Lange sold 28,186 shares of the stock in a transaction on Friday, March 6th. The stock was sold at an average price of $29.41, for a total value of $828,950.26. The…
Nuvectis Pharma (NASDAQ:NVCT) Shares Up 6.3% - Still a Buy?
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report)'s stock price shot up 6.3% on Tuesday. The company traded as high as $9.88 and last traded at $9.65. 94,856 shares traded hands during trading, an increase of 86% from the average session volume…
Ascendis Pharma A/S $ASND Position Increased by Capital International Investors
Capital International Investors boosted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The…
Spyglass Pharma, Inc.'s Quiet Period Will Expire on March 18th (NASDAQ:SGP)
Spyglass Pharma's (NASDAQ:SGP - Get Free Report) quiet period will end on Wednesday, March 18th. Spyglass Pharma had issued 9,375,000 shares in its initial public offering on February 6th. The total size of the offering was $150,000,000 based on an…
Capital International Investors Raises Stock Holdings in Royalty Pharma PLC $RPRX
Capital International Investors boosted its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 24.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,212,694…
BridgeBio Pharma (NASDAQ:BBIO) Trading Up 9.3% - Should You Buy?
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) shot up 9.3% on Tuesday. The company traded as high as $70.49 and last traded at $71.7590. 1,265,413 shares traded hands during mid-day trading, a decline of 60% from the average…
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at William Blair
Investment analysts at William Blair started coverage on shares of BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) in a research note issued to investors on Tuesday. The firm set an 'outperform' rating on the stock. BridgeBio's Volatile Week Puts…
Receive a Daily briefing on Pharma Industry News
Get Started